JAK Inhibitors Show No Excess CV Safety Signal JAK Inhibitors Show No Excess CV Safety Signal

Compared with adalimumab, JAK inhibitors presented no higher risk for major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Rheumatology News Source Type: news